ClinicalTrials.gg
CompletedNCT03575871JADE Mono-2Updated Apr 21, 2020Results posted

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of PF-04965842 100 mg and PF-04965842 200 mg in Dermatitis, Atopic, sponsored by Pfizer. Completed at 115 sites in 13 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-04-21.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
391
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
6th of 20
391 · median 150
Started
2018
with 4 others
Phase 3
10 of 20
2 open now
Registered
5th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 6th largest by enrollment, is one of 5 that started in 2018, is one of 10 in phase 3, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • atopic dermatitis
  • atopic eczema
  • eczema
  • JAK
  • janus kinase
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 years of age or older with a minimum body weight of 40 kg
  • Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)
  • Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control

Exclusion criteria

Exclusion Criteria:

  • Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
  • Prior treatment with JAK inhibitors
  • Other active nonAD inflammatory skin diseases or conditions affecting skin
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
  • Pregnant or breastfeeding women, or women of who are unwilling to use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
391 participants (actual)

Study arms

  • Experimental
    PF-04965842 100 mg

    Drug: PF-04965842 100 mg

  • Experimental
    PF-04965842 200 mg

    Drug: PF-04965842 200 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks

  • DrugPlacebo

    Placebo, administered as two tablets to be taken orally once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

    IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp.

    Time frame: Baseline, Week 12

  2. Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12

    EASI evaluates severity of participants AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\] on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved at Least 4-Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Weeks 2, 4, 8 and 12

    Participants were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  2. Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12

    PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \[lighter or darker\], bleeding from skin, seeping or oozing fluid from skin \[other than blood\], and skin swelling). Participant had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.

    Time frame: Baseline, Week 12

  3. Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus

    Participants were asked to assess their worst itching/pruritus due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst itch imaginable), where higher scores indicated greater severity.

    Time frame: Baseline up to Day 15

  4. Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75% Improvement (EASI-75) From Baseline at Weeks 2, 4 and 8

    EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, and 8

  5. Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Weeks 2, 4 and 8

    IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp.

    Time frame: Baseline, Weeks 2, 4, and 8

  6. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) at Week 2, 4, 8 and 12

    IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp.

    Time frame: Weeks 2, 4, 8 and 12

  7. Percentage of Participants Achieving Eczema Area and Severity Index Response of >=50% Improvement (EASI-50) From Baseline at Weeks 2, 4, 8 and 12

    EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  8. Percentage of Participants Achieving Eczema Area and Severity Index Response of >=90% Improvement (EASI-90) From Baseline at Weeks 2, 4, 8 and 12

    EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  9. Percentage of Participants Achieving Eczema Area and Severity Index Response of 100% Improvement (EASI-100) From Baseline at Weeks 2, 4, 8 and 12

    EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  10. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 8 and 12

    EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  11. Change From Baseline in the Percentage Body Surface Area (%BSA) Affected at Week 2, 4, 8, and 12

    4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  12. Percentage of Participants With Percentage Body Surface Area (%BSA) (From EASI) < 5% at Weeks 2, 4, 8 and 12

    4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limb, 3.33% for trunk and 2.5% for lower limb. % BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.

    Time frame: Weeks 2, 4, 8, and 12

  13. Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8 and 12

    SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where "0" = no itch/no sleeplessness and "10" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  14. Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=75% Improvement From Baseline at Week 2, 4, 8 and 12

    SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  15. Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch at Weeks 2, 4, 8 and 12

    SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  16. Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12

    SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

  17. Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8 and 12

    SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8, and 12

07

Results

Posted Apr 21, 2020

Participant flow

Participants with age greater than or equal to (\>=) 12 years with moderate to severe atopic dermatitis (AD) and a body weight of \>=40 kilograms were enrolled in the study. Eligible participants had an option to enter into a long-term extension (LTE) study after completing 12 weeks of treatment in this study.

Participant flow — Overall Study
MilestonePF-04965842 100 mgPF-04965842 200 mgPlacebo
Started15815578
Completed13714152
Not completed211426
Withdrew: Adverse event558
Withdrew: Death100
Withdrew: Lack of efficacy547
Withdrew: Lost to follow-up111
Withdrew: Protocol deviation111
Withdrew: Withdrawal by subject619
Withdrew: Other than specified220

Outcome measures

PrimaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 1228.4 (21.3 to 35.5)38.1 (30.4 to 45.7)9.1 (2.7 to 15.5)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0008 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 19.3 · 95% CI 9.6 to 29.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 28.7 · 95% CI 18.6 to 38.8
PrimaryPercentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12

EASI evaluates severity of participants AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\] on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75 Percent (%) Improvement (EASI-75) From Baseline at Week 1244.5 (36.7 to 52.3)61.0 (53.3 to 68.7)10.4 (3.6 to 17.2)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 33.9 · 95% CI 23.3 to 44.4
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 50.5 · 95% CI 40.0 to 60.9
SecondaryPercentage of Participants Who Achieved at Least 4-Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Weeks 2, 4, 8 and 12

Participants were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved at Least 4-Points Improvement From Baseline in the Numerical Rating Scale (NRS) for Severity of Pruritus at Weeks 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 223.1 (16.5 to 29.7)35.3 (27.7 to 42.9)3.9 (0.0 to 8.3)
Week 431.4 (24.1 to 38.7)50.3 (42.4 to 58.2)3.9 (0.0 to 8.3)
Week 839.1 (31.4 to 46.8)51.6 (43.7 to 59.6)11.8 (4.6 to 19.1)
Week 1239.7 (32.1 to 47.4)49.0 (41.1 to 56.9)10.5 (3.6 to 17.4)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0002 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 19.2 · 95% CI 11.0 to 27.4
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 31.2 · 95% CI 22.3 to 40.2
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 27.5 · 95% CI 18.9 to 36.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 46.4 · 95% CI 37.2 to 55.7
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 27.4 · 95% CI 16.8 to 38.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 39.8 · 95% CI 28.9 to 50.6
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 29.3 · 95% CI 18.9 to 39.6
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 38.6 · 95% CI 28.1 to 49.1
SecondaryChange From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12

PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \[lighter or darker\], bleeding from skin, seeping or oozing fluid from skin \[other than blood\], and skin swelling). Participant had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12
units on a scalePF-04965842 100 mgPF-04965842 200 mgPlacebo
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score at Week 12-2.4 (-2.8 to -2.1)-3.0 (-3.3 to -2.7)-0.8 (-1.3 to -0.3)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.7 · 95% CI -2.3 to -1.1
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.2 · 95% CI -2.8 to -1.6
SecondaryTime to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus

Participants were asked to assess their worst itching/pruritus due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst itch imaginable), where higher scores indicated greater severity.

Time frame:
Baseline up to Day 15
Reported as:
Median · days
Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus
daysPF-04965842 100 mgPF-04965842 200 mgPlacebo
Time to Achieve >=4 Points Improvement From Baseline in Numerical Rating Scale (NRS) for Severity of Pruritus58.0 (11.0 to NA)29.0 (8.0 to 87.0)112.0 (58.0 to NA)
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index Response of >=75% Improvement (EASI-75) From Baseline at Weeks 2, 4 and 8

EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index Response of >=75% Improvement (EASI-75) From Baseline at Weeks 2, 4 and 8
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 210.2 (5.5 to 14.9)24.3 (17.5 to 31.2)1.3 (0.0 to 3.9)
Week 426.5 (19.5 to 33.4)51.0 (43.1 to 58.9)6.5 (1.0 to 12.0)
Week 843.3 (35.6 to 51.1)60.4 (52.7 to 68.1)12.8 (5.4 to 20.2)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0150 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 8.8 · 95% CI 2.8 to 14.9
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 22.7 · 95% CI 15.0 to 30.3
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0004 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 20.0 · 95% CI 10.9 to 29.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 44.3 · 95% CI 34.8 to 53.8
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 30.4 · 95% CI 19.7 to 41.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 47.4 · 95% CI 36.8 to 58.0
SecondaryPercentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Weeks 2, 4 and 8

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp.

Time frame:
Baseline, Weeks 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Weeks 2, 4 and 8
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 25.1 (1.7 to 8.5)14.5 (8.9 to 20.1)0 (0.0 to 4.7)
Week 414.2 (8.7 to 19.7)33.3 (25.9 to 40.8)1.3 (0.0 to 3.8)
Week 822.3 (15.8 to 28.8)37.7 (30.0 to 45.3)10.3 (3.5 to 17.0)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0459 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 5.1 · 95% CI 0.2 to 10.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0005 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 14.2 · 95% CI 7.8 to 20.5
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0019 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 12.9 · 95% CI 6.3 to 19.4
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 31.8 · 95% CI 23.6 to 39.9
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0246 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 11.9 · 95% CI 2.4 to 21.4
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 26.9 · 95% CI 17.0 to 36.9
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) at Week 2, 4, 8 and 12

IGA assesses severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded soles, palms and scalp.

Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) at Week 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 20 (0.0 to 2.3)2.0 (0.0 to 4.2)0 (0.0 to 4.7)
Week 41.9 (0.0 to 4.1)4.6 (1.3 to 7.9)0 (0.0 to 4.7)
Week 81.3 (0.0 to 3.0)4.5 (1.3 to 7.8)0 (0.0 to 4.6)
Week 125.2 (1.7 to 8.6)6.5 (2.6 to 10.3)0 (0.0 to 4.7)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Difference in percentage: 0.0 · 95% CI -3.7 to 3.7
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2262 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.9 · 95% CI -2.2 to 6.1
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2223 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.9 · 95% CI -2.2 to 6.1
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0597 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 4.5 · 95% CI -0.2 to 9.2
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3207 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.3 · 95% CI -2.7 to 5.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0586 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 4.5 · 95% CI -0.2 to 9.2
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0419 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 5.2 · 95% CI 0.3 to 10.1
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0244 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 6.3 · 95% CI 1.2 to 11.4
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index Response of >=50% Improvement (EASI-50) From Baseline at Weeks 2, 4, 8 and 12

EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index Response of >=50% Improvement (EASI-50) From Baseline at Weeks 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 235.7 (28.2 to 43.2)55.3 (47.4 to 63.2)10.5 (3.6 to 17.4)
Week 458.7 (51.0 to 66.5)78.4 (71.9 to 84.9)28.6 (18.5 to 38.7)
Week 866.2 (58.8 to 73.6)82.5 (76.5 to 88.5)34.6 (24.1 to 45.2)
Week 1268.4 (61.1 to 75.7)79.9 (73.5 to 86.2)19.5 (10.6 to 28.3)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 25.0 · 95% CI 14.8 to 35.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 44.2 · 95% CI 33.9 to 54.6
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 30.2 · 95% CI 17.5 to 42.8
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 49.8 · 95% CI 37.8 to 61.7
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 31.5 · 95% CI 18.8 to 44.3
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 47.6 · 95% CI 35.7 to 59.6
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 48.7 · 95% CI 37.2 to 60.1
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 60.1 · 95% CI 49.1 to 71.0
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index Response of >=90% Improvement (EASI-90) From Baseline at Weeks 2, 4, 8 and 12

EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index Response of >=90% Improvement (EASI-90) From Baseline at Weeks 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 22.5 (0.1 to 5.0)9.2 (4.6 to 13.8)0 (0.0 to 4.7)
Week 49.7 (5.0 to 14.3)22.9 (16.2 to 29.5)0 (0.0 to 4.7)
Week 817.2 (11.3 to 23.1)34.4 (26.9 to 41.9)2.6 (0.0 to 6.1)
Week 1223.9 (17.2 to 30.6)37.7 (30.0 to 45.3)3.9 (0.0 to 8.2)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1623 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 2.5 · 95% CI -1.7 to 6.8
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0070 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 9.1 · 95% CI 3.4 to 14.7
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0049 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 9.7 · 95% CI 4.0 to 15.4
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 22.9 · 95% CI 15.5 to 30.2
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0013 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 14.6 · 95% CI 7.2 to 22.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 31.6 · 95% CI 23.1 to 40.1
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 20.1 · 95% CI 11.9 to 28.3
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentage: 33.5 · 95% CI 24.6 to 42.5
SecondaryPercentage of Participants Achieving Eczema Area and Severity Index Response of 100% Improvement (EASI-100) From Baseline at Weeks 2, 4, 8 and 12

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index Response of 100% Improvement (EASI-100) From Baseline at Weeks 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 20 (0.0 to 2.3)1.3 (0.0 to 3.1)0 (0.0 to 4.7)
Week 41.3 (0.0 to 3.1)3.9 (0.8 to 7.0)0 (0.0 to 4.7)
Week 81.3 (0.0 to 3.0)3.9 (0.8 to 7.0)0 (0.0 to 4.6)
Week 125.2 (1.7 to 8.6)7.1 (3.1 to 11.2)0 (0.0 to 4.7)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Difference in percentage: 0.0 · 95% CI -3.7 to 3.7
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3261 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.3 · 95% CI -2.8 to 5.3
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3207 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.3 · 95% CI -2.7 to 5.3
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0810 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 3.9 · 95% CI -0.8 to 8.5
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3207 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.3 · 95% CI -2.7 to 5.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0810 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 3.8 · 95% CI -0.7 to 8.4
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0419 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 5.2 · 95% CI 0.3 to 10.1
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0180 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 7.0 · 95% CI 1.8 to 12.2
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 8 and 12

EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\] and lower limbs \[including buttocks\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 2, 4, 8 and 12
percent changePF-04965842 100 mgPF-04965842 200 mgPlacebo
Change at Week 2-39.2 (-43.8 to -34.7)-51.3 (-55.9 to -46.7)-9.0 (-15.4 to -2.5)
Change at Week 4-54.3 (-59.1 to -49.5)-69.0 (-73.7 to -64.2)-24.4 (-31.1 to -17.7)
Change at Week 8-59.5 (-65.0 to -54.0)-73.2 (-78.7 to -67.7)-33.0 (-41.1 to -25.0)
Change at Week 12-60.0 (-66.5 to -53.6)-73.3 (-79.7 to -66.9)-28.6 (-38.4 to -18.8)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -30.2 · 95% CI -38.1 to -22.3
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -42.3 · 95% CI -50.3 to -34.4
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -29.9 · 95% CI -38.1 to -21.7
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -44.6 · 95% CI -52.8 to -36.3
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -26.4 · 95% CI -36.2 to -16.7
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -40.2 · 95% CI -50.0 to -30.4
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -31.4 · 95% CI -43.1 to -19.7
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -44.7 · 95% CI -56.4 to -33.0
SecondaryChange From Baseline in the Percentage Body Surface Area (%BSA) Affected at Week 2, 4, 8, and 12

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Least squares mean · percentage of BSA
Change From Baseline in the Percentage Body Surface Area (%BSA) Affected at Week 2, 4, 8, and 12
percentage of BSAPF-04965842 100 mgPF-04965842 200 mgPlacebo
Change at Week 2-27.8 (-33.0 to -22.6)-35.4 (-40.6 to -30.2)-1.3 (-8.7 to 6.0)
Change at Week 4-45.0 (-50.4 to -39.6)-55.7 (-61.1 to -50.3)-15.3 (-22.9 to -7.7)
Change at Week 8-53.4 (-60.0 to -46.8)-61.1 (-67.7 to -54.5)-20.5 (-30.1 to -10.9)
Change at Week 12-56.4 (-63.1 to -49.6)-65.0 (-71.7 to -58.3)-16.8 (-26.9 to -6.6)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -26.5 · 95% CI -35.5 to -17.5
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -34.1 · 95% CI -43.1 to -25.1
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -29.7 · 95% CI -39.0 to -20.4
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -40.5 · 95% CI -49.8 to -31.1
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -32.9 · 95% CI -44.6 to -21.2
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -40.6 · 95% CI -52.2 to -28.9
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -39.6 · 95% CI -51.8 to -27.4
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -48.2 · 95% CI -60.4 to -36.0
SecondaryPercentage of Participants With Percentage Body Surface Area (%BSA) (From EASI) < 5% at Weeks 2, 4, 8 and 12

4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limb, 3.33% for trunk and 2.5% for lower limb. % BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.

Time frame:
Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants With Percentage Body Surface Area (%BSA) (From EASI) < 5% at Weeks 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 21.9 (0.0 to 4.1)5.9 (2.2 to 9.7)0 (0.0 to 4.7)
Week 46.5 (2.6 to 10.3)17.0 (11.0 to 22.9)0 (0.0 to 4.7)
Week 815.9 (10.2 to 21.6)27.3 (20.2 to 34.3)1.3 (0.0 to 3.8)
Week 1222.6 (16.0 to 29.2)34.4 (26.9 to 41.9)3.9 (0.0 to 8.2)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2353 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.9 · 95% CI -2.2 to 6.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0332 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 5.8 · 95% CI 0.8 to 10.8
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0227 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 6.5 · 95% CI 1.4 to 11.6
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 16.8 · 95% CI 10.1 to 23.5
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0008 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 14.5 · 95% CI 7.7 to 21.3
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 25.8 · 95% CI 18.1 to 33.4
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0003 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 18.5 · 95% CI 10.5 to 26.5
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 30.2 · 95% CI 21.4 to 39.0
SecondaryPercentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8 and 12

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where "0" = no itch/no sleeplessness and "10" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 212.7 (7.5 to 18.0)32.9 (25.4 to 40.4)0 (0.0 to 4.7)
Week 436.1 (28.6 to 43.7)60.8 (53.0 to 68.5)7.8 (1.8 to 13.8)
Week 843.3 (35.6 to 51.1)61.7 (54.0 to 69.4)15.4 (7.4 to 23.4)
Week 1249.0 (41.2 to 56.9)62.6 (55.0 to 70.2)12.8 (5.4 to 20.2)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0011 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 12.7 · 95% CI 6.5 to 18.9
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 32.6 · 95% CI 24.6 to 40.6
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 28.3 · 95% CI 18.5 to 38.2
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 52.8 · 95% CI 43.2 to 62.5
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 28.0 · 95% CI 17.0 to 39.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 46.1 · 95% CI 35.2 to 57.1
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 36.2 · 95% CI 25.4 to 47.1
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 49.6 · 95% CI 38.9 to 60.3
SecondaryPercentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=75% Improvement From Baseline at Week 2, 4, 8 and 12

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response >=75% Improvement From Baseline at Week 2, 4, 8 and 12
percentage of participantsPF-04965842 100 mgPF-04965842 200 mgPlacebo
Week 21.9 (0.0 to 4.1)5.3 (1.7 to 8.8)0 (0.0 to 4.7)
Week 47.1 (3.1 to 11.1)17.6 (11.6 to 23.7)0 (0.0 to 4.7)
Week 811.5 (6.5 to 16.4)26.0 (19.0 to 32.9)0 (0.0 to 4.6)
Week 1218.7 (12.6 to 24.8)30.3 (23.1 to 37.6)2.6 (0.0 to 6.1)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2261 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 1.9 · 95% CI -2.2 to 6.0
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0451 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 5.2 · 95% CI 0.3 to 10.0
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0171 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 7.0 · 95% CI 1.8 to 12.3
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 17.7 · 95% CI 10.9 to 24.5
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0018 (P-value was adjusted by randomization strata (baseline disease severity and age category)) · Difference in percentage: 11.5 · 95% CI 5.5 to 17.5
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category)) · Difference in percentage: 25.7 · 95% CI 18.3 to 33.1
  • PF-04965842 100 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0005 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 16.2 · 95% CI 8.8 to 23.6
  • PF-04965842 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was adjusted by randomization strata (baseline disease severity and age category).) · Difference in percentage: 27.6 · 95% CI 19.3 to 35.8
SecondaryChange From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch at Weeks 2, 4, 8 and 12

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) of Itch at Weeks 2, 4, 8 and 12
units on a scalePF-04965842 100 mgPF-04965842 200 mgPlacebo
Change at Week 2-2.3 (-2.7 to -2.0)-3.5 (-3.8 to -3.1)-0.6 (-1.1 to -0.1)
Change at Week 4-3.1 (-3.5 to -2.7)-4.3 (-4.6 to -3.9)-1.2 (-1.7 to -0.6)
Change at Week 8-3.4 (-3.8 to -3.0)-4.3 (-4.7 to -4.0)-1.8 (-2.4 to -1.2)
Change at Week 12-3.5 (-3.9 to -3.1)-4.2 (-4.7 to -3.8)-2.1 (-2.7 to -1.4)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.7 · 95% CI -2.3 to -1.1
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.9 · 95% CI -3.5 to -2.3
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.9 · 95% CI -2.6 to -1.3
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -3.1 · 95% CI -3.8 to -2.5
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.6 · 95% CI -2.3 to -0.9
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.6 · 95% CI -3.3 to -1.9
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = 0.0006 · Difference in ls mean: -1.4 · 95% CI -2.2 to -0.6
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.2 · 95% CI -3.0 to -1.4
SecondaryChange From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Visual Analogue Scale (VAS) Sleep Loss at Weeks 2, 4, 8 and 12
units on a scalePF-04965842 100 mgPF-04965842 200 mgPlacebo
Change at Week 2-1.9 (-2.2 to -1.5)-2.9 (-3.3 to -2.5)-0.5 (-1.0 to 0.0)
Change at Week 4-2.8 (-3.1 to -2.4)-3.9 (-4.3 to -3.6)-1.0 (-1.5 to -0.5)
Change at Week 8-3.1 (-3.5 to -2.7)-3.9 (-4.3 to -3.5)-1.5 (-2.1 to -0.9)
Change at Week 12-3.0 (-3.4 to -2.6)-3.8 (-4.2 to -3.4)-2.1 (-2.7 to -1.5)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.4 · 95% CI -2.0 to -0.8
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.4 · 95% CI -3.0 to -1.8
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.8 · 95% CI -2.4 to -1.2
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -3.0 · 95% CI -3.6 to -2.3
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.6 · 95% CI -2.3 to -0.9
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -2.4 · 95% CI -3.1 to -1.7
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = 0.0164 · Difference in ls mean: -0.9 · 95% CI -1.7 to -0.2
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -1.7 · 95% CI -2.5 to -1.0
SecondaryPercent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8 and 12

SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2) or severe (3). The severity scores added to give B (0-18). Subjective symptoms (C): pruritus and sleep loss, each of these 2 were scored by participant/caregiver using VAS where "0" = no itch or no sleeplessness and "10" = the worst imaginable itch or sleeplessness, higher scores worse symptoms. Scores for itch and sleeplessness added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\*B/2 + C; range from 0 to 103; higher values of SCORAD = worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8, and 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8 and 12
percent changePF-04965842 100 mgPF-04965842 200 mgPlacebo
Change at Week 2-27.2 (-30.5 to -23.9)-38.5 (-41.8 to -35.1)-6.3 (-11.0 to -1.6)
Change at Week 4-38.9 (-42.6 to -35.1)-53.1 (-56.9 to -49.4)-17.2 (-22.5 to -12.0)
Change at Week 8-42.6 (-46.7 to -38.4)-56.7 (-60.9 to -52.6)-23.1 (-29.2 to -17.1)
Change at Week 12-45.8 (-50.9 to -40.7)-56.2 (-61.2 to -51.1)-22.7 (-30.4 to -15.1)
Statistical analysis
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -20.9 · 95% CI -26.6 to -15.1
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -32.1 · 95% CI -37.9 to -26.4
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -21.6 · 95% CI -28.1 to -15.2
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -35.9 · 95% CI -42.3 to -29.4
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -19.4 · 95% CI -26.8 to -12.1
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -33.6 · 95% CI -41.0 to -26.3
  • PF-04965842 100 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -23.1 · 95% CI -32.3 to -13.9
  • PF-04965842 200 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Difference in ls mean: -33.4 · 95% CI -42.6 to -24.3

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-04965842 100 mg1/158 (0.6%)5/158 (3.2%)56/158 (35.4%)
PF-04965842 200 mg0/155 (0%)2/155 (1.3%)52/155 (33.5%)
Placebo0/78 (0%)1/78 (1.3%)22/78 (28.2%)
Most frequent serious events
Most frequent serious events
EventPF-04965842 100 mgPF-04965842 200 mgPlacebo
Eczema herpeticumInfections and infestations0/1580/1551/78
Staphylococcal skin infectionInfections and infestations0/1580/1551/78
Anaphylactic shockImmune system disorders0/1581/1550/78
Femoral neck fractureInjury, poisoning and procedural complications0/1581/1550/78
Sudden deathGeneral disorders1/1580/1550/78
HerpanginaInfections and infestations1/1580/1550/78
Osteomyelitis bacterialInfections and infestations1/1580/1550/78
PneumoniaInfections and infestations1/1580/1550/78
Staphylococcal infectionInfections and infestations1/1580/1550/78
Dermatitis atopicSkin and subcutaneous tissue disorders1/1580/1550/78
Most frequent other events
Most frequent other events
EventPF-04965842 100 mgPF-04965842 200 mgPlacebo
Dermatitis atopicSkin and subcutaneous tissue disorders9/1586/15512/78
NauseaGastrointestinal disorders12/15822/1552/78
NasopharyngitisInfections and infestations20/15812/1555/78
Upper respiratory tract infectionInfections and infestations14/1585/1553/78
HeadacheNervous system disorders9/15812/1552/78
AcneSkin and subcutaneous tissue disorders2/1589/1550/78
VomitingGastrointestinal disorders2/1588/1551/78

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)PF-04965842 100 mgPF-04965842 200 mgPlaceboTotal
Mean37.4 ± 15.833.5 ± 14.733.4 ± 13.835.1 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)PF-04965842 100 mgPF-04965842 200 mgPlaceboTotal
Female646731162
Male948847229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-04965842 100 mgPF-04965842 200 mgPlaceboTotal
Hispanic or Latino3429
Not Hispanic or Latino15415073377
Unknown or Not Reported1135
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-04965842 100 mgPF-04965842 200 mgPlaceboTotal
American Indian or Alaska Native0000
Asian465429129
Native Hawaiian or Other Pacific Islander0000
Black or African American96621
White1019140232
More than one race1214
Unknown or Not Reported1225
08

Study locations

115 sites
  • Emmaus Research Center, Inc.
    Anaheim, California 92804, United States
  • Advanced Research Center, Inc. - Los Alamitos Site
    Los Alamitos, California 90720, United States
  • Peninsula Research Associates, Inc.
    Rolling Hills Estates, California 90274, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Asthma and Allergy Associates, PC
    Colorado Springs, Colorado 80907, United States
  • Colorado Springs Dermatology Clinic, PC
    Colorado Springs, Colorado 80910, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Precision Imaging
    Jacksonville, Florida 32256, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32801, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Imaging Center of Idaho
    Caldwell, Idaho 83605, United States
  • ASR, LLC
    Nampa, Idaho 83687, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70808, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • MediSearch Clinical Trials
    Saint Joseph, Missouri 64506, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28411, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • The Ohio State University Dermatology East
    Gahanna, Ohio 43230, United States
  • Tanenbaum Dermatology Center
    Memphis, Tennessee 38117, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Austin Institute for Clinical Research, Inc. - Central
    Austin, Texas 78705, United States
  • Center for Clinical Studies, LTD. LLP
    Houston, Texas 77004, United States
  • West Houston Dermatology, PA
    Houston, Texas 77082, United States
  • Summit Clinical Research, LLC
    Franklin, Virginia 23851, United States
  • Virginia Dermatology and Skin Cancer Center
    Norfolk, Virginia 23502, United States
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Veracity Clinical Research Pty Ltd
    Woolloongabba, Queensland 4102, Australia
  • Skin and Cancer Foundation Inc
    Carlton, Victoria, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • The Royal Children's Hospital (RCH)
    Parkville, Victoria 3052, Australia
  • Medical Centre Asklepii OOD
    Dupnitsa, 2600, Bulgaria
  • MHAT Dr. Tota Venkova AD
    Gabrovo, 5300, Bulgaria
  • "Acibadem City Clinic MHAT Tokuda" EAD
    Sofia, 1407, Bulgaria
  • "DCC Aleksandrovska" EOOD
    Sofia, 1431, Bulgaria
  • Diagnostic Consultative Center Fokus-5
    Sofia, 1463, Bulgaria
  • Medical Centre Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • University of British Columbia Department of Dermatology and Skin Science
    Vancouver, British Columbia V5Z 4E8, Canada
  • Winnipeg Clinic
    Winnipeg, Manitoba R3C 0N2, Canada
  • North York Research Inc.
    North York, Ontario M2M 4J5, Canada
  • Oshawa Clinic Dermatology Trials
    Oshawa, Ontario L1H 1B9, Canada
  • York Dermatology Clinic and Research Centre
    Richmond Hill, Ontario L4C 9M7, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N2, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • The Second Affiliated Hospital of Army Medical University, PLA
    Chongqing, Chongqing 400037, China
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
  • Tianjin Medical University General Hospital, Dermatological Department
    Tianjin, 300052, China
  • Dermamedica S.R.O.
    Nachod, 547 01, Czechia
  • Oblastni nemocnice Nachod a.s., Radiodiagnosticke oddeleni
    Nachod, 547 01, Czechia
  • Lekarna u Stribrneho orla
    Nachod, 54701, Czechia
  • Sanatorium profesora Arenbergera
    Praha 1, 11000, Czechia
  • Lekarna U sv. Ignace
    Praha 2, 120 00, Czechia
  • Dermatologicka Ambulance
    Svitavy, 568 02, Czechia
  • Lekarna na Hranicni
    Svitavy, 56802, Czechia
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • ISA GmbH
    Berlin, 10789, Germany
  • Fachärztliche Gemeinschaftspraxis für Dermatologie und Venerologie, Allergologie,
    Blankenfelde-Mahlow, 15831, Germany
  • IKF Pneumologie GmbH & Co KG
    Frankfurt, 60596, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, 20253, Germany
  • Universitaet Muenster
    Münster, 48149, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • SE AOK Bor, Nemikortani es Boronkologiai Klinika
    Budapest, 1085, Hungary
  • Budapest Főváros XIX. Kerületi Önkormányzat Kispesti Egészsegügyi Intézete
    Budapest, 1195, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • ALLERGO-DERM BAKOS Kft.
    Szolnok, 5000, Hungary
  • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    Yokohama, Kanagawa 220-6208, Japan
  • Noguchi Dermatology Clinic
    Kamimashiki-gun, Kumamoto 861-3101, Japan
  • Yoshioka Dermatology Clinic
    Neyagawa, Osaka 572-0838, Japan
  • Kume Clinic
    Sakai, Osaka 593-8324, Japan
  • Sumire Dermatology Clinic
    Edogawa-ku, Tokyo 133-0057, Japan
  • Matsuyama Dermatology Clinic
    Nakano-ku, Tokyo 165-0026, Japan
  • Hoshikuma Dermatology・Allergy Clinic
    Fukuoka, 814-0171, Japan
  • Sanrui Hifuka
    Saitama, 330-0854, Japan
  • Soon Chun Hyang University Bucheon Hospital
    Bucheon-si, Gyeonggi-do 14584, Korea, Republic of
  • The Catholic University of Korea, Incheon St.Mary's Hospital
    Bupyeong-gu, Incheon 21431, Korea, Republic of
  • Inha University Hospital
    Jung-gu, Incheon 22332, Korea, Republic of
  • Kyungpook National University Hospital
    Daegu, 41944, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Severance Hospital, Yonsei Univ. Health System
    Seoul, 03722, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Chung-Ang University Hospital
    Seoul, 06973, Korea, Republic of
  • Hallym university Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
  • Selga Freiberga private practice in dermatovenerology and cosmetology
    Jelgava, LV-3001, Latvia
  • Riga 1st Hospital, Clinic for Dermatology and STD
    Riga, LV-1001, Latvia
  • Aesthetic dermatology clinic of Prof. J. Kisis
    Riga, LV-1003, Latvia
  • Health Centre 4 Ltd. Diagnostics Centre
    Riga, LV-1003, Latvia
  • Health Centre 4 Ltd
    Riga, LV-1013, Latvia
  • NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL s.c.
    Bialystok, 15-453, Poland
  • KLIMED Marek Klimkiewicz
    Białystok, 15-704, Poland
  • Centrum Nowoczesnych Terapii "DOBRY LEKARZ" sp. z o. o.
    Krakow, 31-011, Poland
  • Centrum Badań Klinicznych JCI
    Kraków, 30-348, Poland
  • Krakowskie Centrum Medyczne Sp. z o.o.
    Kraków, 31-501, Poland
  • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
    Lodz, 90-242, Poland

Showing the first 100 of 115 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug;33(5):2605-2613. doi: 10.1080/09546634.2022.2059053. Epub 2022 Jul 6. PubMed 35763326 ↗
  • Stander S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, DiBonaventura M, Romero W, Farooqui SA. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1308-1317. doi: 10.1111/jdv.18170. Epub 2022 May 6. PubMed 35462428 ↗
  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib. Br J Clin Pharmacol. 2022 Aug;88(8):3856-3871. doi: 10.1111/bcp.15334. Epub 2022 Apr 11. PubMed 35342978 ↗
  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21. Erratum In: Clin Pharmacokinet. 2022 Apr;61(4):591. doi: 10.1007/s40262-022-01112-7. PubMed 35061234 ↗
  • Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE, DiBonaventura M. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):422-433. doi: 10.1111/jdv.17792. Epub 2021 Dec 4. PubMed 34743361 ↗
  • Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, Egeberg A, Valdez H, Zhang M, Farooqui SA, Romero W, Thorpe AJ, Rojo R, Johnson S. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum In: Am J Clin Dermatol. 2021 Nov;22(6):905. doi: 10.1007/s40257-021-00638-z. PubMed 34406619 ↗
  • Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Stander S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. Am J Clin Dermatol. 2021 Jul;22(4):541-554. doi: 10.1007/s40257-021-00604-9. Epub 2021 May 5. Erratum In: Am J Clin Dermatol. 2021 Sep;22(5):739. doi: 10.1007/s40257-021-00634-3. PubMed 33954933 ↗
  • Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Aug 1;156(8):863-873. doi: 10.1001/jamadermatol.2020.1406. PubMed 32492087 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2019, 13 months.

Results were first posted in Apr 2020, 8 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Jul 3, 2018
StartActual
Jun 29, 2018
Primary completionActual
Aug 13, 2019
CompletionActual
Aug 13, 2019
Results first posted
Apr 21, 2020
Last update
Apr 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03575871
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 3, 2018
Start date
Jun 29, 2018
Primary completion
Aug 13, 2019
Completion
Aug 13, 2019
Results posted
Apr 21, 2020
Last update
Apr 21, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion